An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Clinical trial NCT03900715 · COMPLETED
Trial details
- NCT number
- NCT03900715
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-20
- Primary completion
- 2022-07-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.